A retrospective study on the efficacy and safety of Endostar with chemotherapy in EGFR-TKI-resistant NSCLC
文献类型：期刊论文
| 作者 | Bing Han1; Yanrong Kang5; Haiji Wang3; Jian Wang1; Rong Shen2; Shuai Liu5; Lu Lu5; Zhigang Sun5; Nan Zhang5 |
| 刊名 | BMC PULMONARY MEDICINE
 |
| 出版日期 | 2023 |
| 卷号 | 23期号:1 |
| ISSN号 | 1471-2466 |
| 英文摘要 | Endostar is a strong angiogenesis inhibitor that is effective in treating non-small cell lung cancer (NSCLC), but the effect of Endostar in the treatment of patients with EGFR-TKI-resistant NSCLC remains unclear. We evaluated the clinical efficacy and safety of Endostar in EGFR-mutant NSCLC patients resistant to EGFR inhibition treatment. |
| 语种 | 英语 |
| 源URL | [http://ir.yic.ac.cn/handle/133337/33273]  |
| 专题 | 烟台海岸带研究所_中科院烟台海岸带研究所知识产出 |
| 作者单位 | 1.山东大学 2.Shandong Provincial Hospital, Shandong First Medical University 3.青岛大学 4.中国科学院烟台海岸带研究所 5.Central Hospital, Shandong First Medical University |
| 推荐引用方式 GB/T 7714 | Bing Han,Yanrong Kang,Haiji Wang,et al. A retrospective study on the efficacy and safety of Endostar with chemotherapy in EGFR-TKI-resistant NSCLC[J]. BMC PULMONARY MEDICINE,2023,23(1). |
| APA | Bing Han.,Yanrong Kang.,Haiji Wang.,Jian Wang.,Rong Shen.,...&Nan Zhang.(2023).A retrospective study on the efficacy and safety of Endostar with chemotherapy in EGFR-TKI-resistant NSCLC.BMC PULMONARY MEDICINE,23(1). |
| MLA | Bing Han,et al."A retrospective study on the efficacy and safety of Endostar with chemotherapy in EGFR-TKI-resistant NSCLC".BMC PULMONARY MEDICINE 23.1(2023). |
入库方式： OAI收割
来源：烟台海岸带研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。